PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer
Conclusions: PTPRF may have value as a predictive marker to identify which patients can obtain the greatest benefit from erlotinib in the post–first-line setting. Further research is warranted to determine the potential value of this marker in clinical decision-making.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Brief Reports Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Study | Tarceva